LLY · News · 20260825N
Revenue Performance and Mix
ELI LILLY & Co · 2026-08-25 · Importance 58 · Surprise 56 · No source text
Eli Lilly reported 48% revenue growth in the second quarter of 2026. Growth was fueled by Mounjaro and Zepbound, its diabetes and obesity therapies. Lilly was described as dominating the U.S. obesity prescription market, indicating continued concentration in GLP-1 products.
Key facts
- Q2 2026 revenue growth: 48% (Lilly reported strong 48% revenue growth in Q2 2026). source
- On Tuesday, ELI LILLY & Co stock fell by 1.06%, closing at $1,233.66. source
- The decline on Tuesday marked the second consecutive day of losses for ELI LILLY & Co shares. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | +32.5% | Q2 2026 revenue growth: 48% (Lilly reported strong 48% revenue growth in Q2 2026). |